Published in Lancet on October 12, 2013
Reconsidering the Declaration of Helsinki. Lancet (2013) 3.15
Reconsidering the Declaration of Helsinki. Lancet (2013) 0.98
Reconsidering the Declaration of Helsinki. Lancet (2013) 0.96
The Affordable Care Act and the future of clinical medicine: the opportunities and challenges. Ann Intern Med (2010) 9.59
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol (2006) 5.40
Principles for allocation of scarce medical interventions. Lancet (2009) 4.55
Ethical issues concerning research in complementary and alternative medicine. JAMA (2004) 4.48
The obligation to participate in biomedical research. JAMA (2009) 4.34
Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med (2002) 3.62
Shared decision making to improve care and reduce costs. N Engl J Med (2013) 3.48
The cost of marginal medicine is too high. MedGenMed (2005) 3.33
Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA (2005) 3.14
The cost of institutional review boards in academic medical centers. N Engl J Med (2005) 3.06
Prescribing "placebo treatments": results of national survey of US internists and rheumatologists. BMJ (2008) 2.84
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol (2004) 2.52
Medicare's requirement for research participation as a condition of coverage: is it ethical? JAMA (2006) 2.43
Research with stored biological samples: what do research participants want? Arch Intern Med (2005) 2.43
The prognosis for changes in end-of-life care after the Schiavo case. Health Aff (Millwood) (2005) 2.40
Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med (2006) 2.29
Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA (2003) 2.28
Ethical guidance on the use of life-sustaining therapies for patients with Ebola in developed countries. Ann Intern Med (2014) 2.19
US health aid beyond PEPFAR: the Mother & Child Campaign. JAMA (2008) 2.17
The 50th anniversary of the Declaration of Helsinki: progress but many remaining challenges. JAMA (2013) 2.16
Community permission for medical research in developing countries. Clin Infect Dis (2005) 2.01
The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs? Am J Public Health (2004) 1.88
The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA (2005) 1.83
The ethics of paying for children's participation in research. J Pediatr (2002) 1.80
What is a "minor" increase over minimal risk? J Pediatr (2005) 1.79
Participants in phase 1 oncology research trials: are they vulnerable? Arch Intern Med (2008) 1.74
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol (2008) 1.71
Will physicians lead on controlling health care costs? JAMA (2013) 1.71
Health care reform and cost control. N Engl J Med (2010) 1.66
Ethics. The ethics of international research with abandoned children. Science (2007) 1.65
Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol (2007) 1.65
Why patients continue to participate in clinical research. Arch Intern Med (2008) 1.62
Ending concerns about undue inducement. J Law Med Ethics (2004) 1.55
Health care reform: why? What? When? Health Aff (Millwood) (2005) 1.50
Regional ethics organizations for protection of human research participants. Nat Med (2004) 1.48
Can primary care visits reduce hospital utilization among Medicare beneficiaries at the end of life? J Gen Intern Med (2008) 1.47
Improving access to health care: a consensus ethical framework to guide proposals for reform. Hastings Cent Rep (2007) 1.47
Access and ability to pay: the ethics of a tiered health care system. Arch Intern Med (2007) 1.46
A historic moment for open science: the Yale University Open Data Access project and medtronic. Ann Intern Med (2013) 1.45
Can the United States buy better advance care planning? Ann Intern Med (2014) 1.41
ASCO core values. J Clin Oncol (2006) 1.40
Quality-improvement research and informed consent. N Engl J Med (2008) 1.40
Does random treatment assignment cause harm to research participants? PLoS Med (2006) 1.39
The transparency imperative. Ann Intern Med (2013) 1.39
The moral duty to buy health insurance. JAMA (2012) 1.38
Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol (2002) 1.37
Tier 4 drugs and the fraying of the social compact. N Engl J Med (2008) 1.16
The quality of informed consent in a clinical research study in Thailand. IRB (2005) 1.13
PEPFAR and maximizing the effects of global health assistance. JAMA (2012) 1.12
Single- vs multiple-fraction radiotherapy for bone metastases from prostate cancer. JAMA (2013) 1.11
Evaluating the risks of clinical research. JAMA (2010) 1.09
Alternative medicine research in clinical practice: a US national survey. Arch Intern Med (2009) 1.07
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer (2007) 1.07
Using Behavioral Economics to Design Physician Incentives That Deliver High-Value Care. Ann Intern Med (2015) 1.01
Clarifying confusions about coercion. Hastings Cent Rep (2005) 1.01
Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ (2004) 0.98
Who's caring for whom? Differing perspectives between seriously ill patients and their family caregivers. Am J Hosp Palliat Care (2006) 0.96
Survey of oncologists about shortages of cancer drugs. N Engl J Med (2013) 0.95
The general agreement on trade in services: implications for health policymakers. Health Aff (Millwood) (2004) 0.94
Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses (2006) 0.94
Why well-insured patients should demand value-based insurance benefits. JAMA (2007) 0.93
Media exposure and tobacco, illicit drugs, and alcohol use among children and adolescents: a systematic review. Subst Abus (2010) 0.92
Considering usual medical care in clinical trial design. PLoS Med (2009) 0.91
The ethics of not hiring smokers. N Engl J Med (2013) 0.91
Circumcision and HIV prevention research: an ethical analysis. Lancet (2006) 0.90
The current state of medical school education in bioethics, health law, and health economics. J Law Med Ethics (2008) 0.90
Patterns of care studies: creating "an environment of watchful concern". J Clin Oncol (2003) 0.90
Depression, euthanasia, and improving end-of-life care. J Clin Oncol (2005) 0.89
Institutional review board review of multicenter studies. Ann Intern Med (2007) 0.88
Reengineering US health care. JAMA (2013) 0.85
Advance directives and cost savings: greater clarity and perpetual confusion. Arch Intern Med (2012) 0.85
The ethics of research in developing countries: assessing voluntariness. Lancet (2005) 0.84
A consent form template for phase I oncology trials. IRB (2009) 0.84
Overcoming the pricing power of hospitals. JAMA (2012) 0.84
Informed consent: practices and views of investigators in a multinational clinical trial. IRB (2006) 0.83
Benefits and burdens of participation in a longitudinal clinical trial. J Empir Res Hum Res Ethics (2009) 0.82
Nursing home residence confounds gender differences in Medicare utilization an example of Simpson's paradox. Womens Health Issues (2010) 0.82
Does the evidence make a difference in consumer behavior? Sales of supplements before and after publication of negative research results. J Gen Intern Med (2008) 0.82
Toward accountable cancer care. JAMA Intern Med (2013) 0.81
Research benefits for hypothetical HIV vaccine trials: The views of Ugandans in the Rakai District. IRB (2008) 0.81
What does a hip replacement cost?: the transparency imperative in 2013. Comment on "Obtaining consumer prices from US hospitals for a common surgical procedure". JAMA Intern Med (2013) 0.80
Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali. Am J Trop Med Hyg (2010) 0.80
Religion, clinicians, and the integration of complementary and alternative medicines. J Altern Complement Med (2009) 0.79
A communitarian health-care package. Responsive Community (1993) 0.79
The ethics of research on enhancement interventions. Kennedy Inst Ethics J (2010) 0.78
Living wills: are durable powers of attorney better? Hastings Cent Rep (2005) 0.78
Factors that influence practitioners' interpretations of evidence from alternative medicine trials: a factorial vignette experiment embedded in a national survey. Med Care (2010) 0.78
Is there coercion or undue inducement to participate in health research in developing countries? An example from Rakai, Uganda. J Clin Ethics (2009) 0.77
Technology licensing: lessons from the US experience. JAMA (2005) 0.76
Institutional review board reform. N Engl J Med (2002) 0.76
Standing by our principles: meaningful guidance, moral foundations, and multi-principle methodology in medical scarcity. Am J Bioeth (2010) 0.75
Reductions in funding for medical research--reply. JAMA (2013) 0.75
Physicians advising investment firms. JAMA (2005) 0.75
"Physician-assisted suicide among Oregon cancer patients": a fading issue. J Clin Ethics (2006) 0.75
Use of Life-Sustaining Therapies for Patients With Ebola Virus Disease. Ann Intern Med (2015) 0.75
Conserving scarce resources: willingness of health insurance enrollees to choose cheaper options. J Law Med Ethics (2004) 0.75
The blossoming of bioethics at NIH. Kennedy Inst Ethics J (1998) 0.75
Legal reforms necessary to promote delivery system innovation. JAMA (2008) 0.75